UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

NOTICE OF EFFECTIVENESS

Effective Date:September 01,
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Can Fite BioPharma Charts.
Can Fite BioPharma (AMEX:CANF)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Can Fite BioPharma Charts.

Can-fite Biopharma Ltd. News

Long-term Complete Response to Can-Fite's Namodenoson in Patient with Advanced Liver Cancer: Article Published in a Leading Scientific Journal
Thursday 25 April 2024 (1 week ago) • Business Wire
Can-Fite: Scientific Article Published by KOL Presents Namodenoson as a Promising Drug Candidate to Treat Advanced Liver Cancer and MASH
Monday 15 April 2024 (3 weeks ago) • Business Wire
Can-Fite: Submits FDA with an IND Application to Conduct Phase IIb Clinical Trial of Namodenoson in MASH Patients
Wednesday 3 April 2024 (4 weeks ago) • Business Wire
Can-Fite Reports 2023 Financial Results and Clinical Update
Thursday 28 March 2024 (1 month ago) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 11 March 2024 (2 months ago) • Edgar (US Regulatory)
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
Monday 11 March 2024 (2 months ago) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Wednesday 28 February 2024 (2 months ago) • Edgar (US Regulatory)
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
Wednesday 28 February 2024 (2 months ago) • Business Wire
Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Wednesday 14 February 2024 (3 months ago) • Edgar (US Regulatory)
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Tuesday 30 January 2024 (3 months ago) • Edgar (US Regulatory)
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
Tuesday 30 January 2024 (3 months ago) • Business Wire
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 29 January 2024 (3 months ago) • Edgar (US Regulatory)

More Can-fite Biopharma Ltd. News Articles